Atossa Therapeutics (ATOS) Projected to Post Quarterly Earnings on Monday

Atossa Therapeutics (NASDAQ:ATOS) is projected to post its quarterly earnings results before the market opens on Monday, April 7th. Analysts expect Atossa Therapeutics to post earnings of ($0.06) per share for the quarter.

Atossa Therapeutics (NASDAQ:ATOS) last posted its quarterly earnings results on Tuesday, March 25th. The company reported ($0.05) EPS for the quarter, beating analysts’ consensus estimates of ($0.06) by $0.01. On average, analysts expect Atossa Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Atossa Therapeutics Price Performance

ATOS stock opened at $0.60 on Friday. Atossa Therapeutics has a 1-year low of $0.60 and a 1-year high of $2.31. The business has a 50 day simple moving average of $0.76 and a two-hundred day simple moving average of $1.07. The company has a market capitalization of $77.64 million, a price-to-earnings ratio of -2.73 and a beta of 1.20.

Institutional Investors Weigh In On Atossa Therapeutics

A hedge fund recently raised its stake in Atossa Therapeutics stock. Bank of America Corp DE grew its holdings in Atossa Therapeutics, Inc. (NASDAQ:ATOS) by 51.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 111,475 shares of the company’s stock after buying an additional 37,809 shares during the period. Bank of America Corp DE owned approximately 0.09% of Atossa Therapeutics worth $105,000 as of its most recent filing with the Securities & Exchange Commission. Hedge funds and other institutional investors own 12.74% of the company’s stock.

Wall Street Analysts Forecast Growth

ATOS has been the subject of a number of research reports. Ascendiant Capital Markets raised their target price on shares of Atossa Therapeutics from $6.50 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 9th. HC Wainwright reissued a “buy” rating and set a $7.00 price objective on shares of Atossa Therapeutics in a report on Wednesday, March 26th.

About Atossa Therapeutics

Atossa Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer.